vs

Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and NewtekOne, Inc. (NEWT). Click either name above to swap in a different company.

NewtekOne, Inc. is the larger business by last-quarter revenue ($73.3M vs $62.1M, roughly 1.2× Cytek Biosciences, Inc.). NewtekOne, Inc. runs the higher net margin — 111.8% vs -70.9%, a 182.7% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs -2.7%). Cytek Biosciences, Inc. produced more free cash flow last quarter ($-1.8M vs $-579.3M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 12.2%).

Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.

NewTek, Inc., is a hardware and software company, based in San Antonio, Texas, that produced live and post-production video tools and visual imaging software for personal computers. The company was founded in 1985 in Topeka, Kansas, United States, by Tim Jenison and Paul Montgomery. On April 1, 2019, it was announced that NewTek would be acquired by Vizrt.

CTKB vs NEWT — Head-to-Head

Bigger by revenue
NEWT
NEWT
1.2× larger
NEWT
$73.3M
$62.1M
CTKB
Growing faster (revenue YoY)
CTKB
CTKB
+10.8% gap
CTKB
8.1%
-2.7%
NEWT
Higher net margin
NEWT
NEWT
182.7% more per $
NEWT
111.8%
-70.9%
CTKB
More free cash flow
CTKB
CTKB
$577.6M more FCF
CTKB
$-1.8M
$-579.3M
NEWT
Faster 2-yr revenue CAGR
CTKB
CTKB
Annualised
CTKB
17.7%
12.2%
NEWT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CTKB
CTKB
NEWT
NEWT
Revenue
$62.1M
$73.3M
Net Profit
$-44.1M
$19.5M
Gross Margin
52.9%
Operating Margin
-9.0%
Net Margin
-70.9%
111.8%
Revenue YoY
8.1%
-2.7%
Net Profit YoY
-557.1%
6.6%
EPS (diluted)
$0.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTKB
CTKB
NEWT
NEWT
Q4 25
$62.1M
$73.3M
Q3 25
$52.3M
$74.9M
Q2 25
$45.6M
$70.2M
Q1 25
$41.5M
$66.3M
Q4 24
$57.5M
$75.4M
Q3 24
$51.5M
$62.8M
Q2 24
$46.6M
$61.1M
Q1 24
$44.9M
$58.3M
Net Profit
CTKB
CTKB
NEWT
NEWT
Q4 25
$-44.1M
$19.5M
Q3 25
$-5.5M
$17.9M
Q2 25
$-5.6M
$13.7M
Q1 25
$-11.4M
$9.4M
Q4 24
$9.6M
$18.3M
Q3 24
$941.0K
$11.9M
Q2 24
$-10.4M
$10.9M
Q1 24
$-6.2M
$9.7M
Gross Margin
CTKB
CTKB
NEWT
NEWT
Q4 25
52.9%
Q3 25
52.7%
Q2 25
52.3%
Q1 25
48.6%
Q4 24
58.5%
Q3 24
56.3%
Q2 24
54.6%
Q1 24
51.3%
Operating Margin
CTKB
CTKB
NEWT
NEWT
Q4 25
-9.0%
Q3 25
-17.6%
Q2 25
-23.3%
Q1 25
-36.1%
Q4 24
5.2%
Q3 24
-8.2%
Q2 24
-18.3%
Q1 24
-23.9%
Net Margin
CTKB
CTKB
NEWT
NEWT
Q4 25
-70.9%
111.8%
Q3 25
-10.5%
23.9%
Q2 25
-12.2%
19.5%
Q1 25
-27.5%
14.1%
Q4 24
16.8%
24.3%
Q3 24
1.8%
19.0%
Q2 24
-22.4%
17.9%
Q1 24
-13.8%
16.6%
EPS (diluted)
CTKB
CTKB
NEWT
NEWT
Q4 25
$0.64
Q3 25
$0.67
Q2 25
$0.52
Q1 25
$0.35
Q4 24
$0.70
Q3 24
$0.45
Q2 24
$0.43
Q1 24
$0.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTKB
CTKB
NEWT
NEWT
Cash + ST InvestmentsLiquidity on hand
$90.9M
Total DebtLower is stronger
$819.9M
Stockholders' EquityBook value
$341.7M
$397.6M
Total Assets
$461.5M
$2.7B
Debt / EquityLower = less leverage
2.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTKB
CTKB
NEWT
NEWT
Q4 25
$90.9M
Q3 25
$93.3M
Q2 25
$75.5M
Q1 25
$95.3M
Q4 24
$98.7M
Q3 24
$162.3M
Q2 24
$177.9M
Q1 24
$168.8M
Total Debt
CTKB
CTKB
NEWT
NEWT
Q4 25
$819.9M
Q3 25
$748.5M
Q2 25
$657.3M
Q1 25
$774.0M
Q4 24
$708.0M
Q3 24
$655.8M
Q2 24
$652.0M
Q1 24
$662.5M
Stockholders' Equity
CTKB
CTKB
NEWT
NEWT
Q4 25
$341.7M
$397.6M
Q3 25
$378.6M
$386.7M
Q2 25
$377.6M
$312.2M
Q1 25
$379.6M
$302.3M
Q4 24
$395.7M
$296.3M
Q3 24
$385.5M
$281.8M
Q2 24
$389.1M
$274.0M
Q1 24
$392.6M
$254.1M
Total Assets
CTKB
CTKB
NEWT
NEWT
Q4 25
$461.5M
$2.7B
Q3 25
$494.9M
$2.4B
Q2 25
$493.3M
$2.1B
Q1 25
$482.6M
$2.1B
Q4 24
$499.5M
$2.1B
Q3 24
$491.2M
$1.7B
Q2 24
$483.7M
$1.6B
Q1 24
$492.1M
$1.5B
Debt / Equity
CTKB
CTKB
NEWT
NEWT
Q4 25
2.06×
Q3 25
1.94×
Q2 25
2.11×
Q1 25
2.56×
Q4 24
2.39×
Q3 24
2.33×
Q2 24
2.38×
Q1 24
2.61×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTKB
CTKB
NEWT
NEWT
Operating Cash FlowLast quarter
$-771.0K
$-579.2M
Free Cash FlowOCF − Capex
$-1.8M
$-579.3M
FCF MarginFCF / Revenue
-2.9%
-790.0%
Capex IntensityCapex / Revenue
1.6%
0.1%
Cash ConversionOCF / Net Profit
-29.64×
TTM Free Cash FlowTrailing 4 quarters
$-8.8M
$-1.0B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTKB
CTKB
NEWT
NEWT
Q4 25
$-771.0K
$-579.2M
Q3 25
$-3.9M
$-167.3M
Q2 25
$108.0K
$-199.8M
Q1 25
$-125.0K
$-60.7M
Q4 24
$2.0M
$-153.0M
Q3 24
$13.2M
$-25.7M
Q2 24
$6.2M
$2.9M
Q1 24
$4.0M
$-38.7M
Free Cash Flow
CTKB
CTKB
NEWT
NEWT
Q4 25
$-1.8M
$-579.3M
Q3 25
$-4.6M
$-167.3M
Q2 25
$-1.5M
$-199.9M
Q1 25
$-974.0K
$-60.7M
Q4 24
$1.1M
$-153.5M
Q3 24
$12.2M
$-25.9M
Q2 24
$5.2M
$2.9M
Q1 24
$3.4M
$-38.7M
FCF Margin
CTKB
CTKB
NEWT
NEWT
Q4 25
-2.9%
-790.0%
Q3 25
-8.7%
-223.3%
Q2 25
-3.2%
-284.7%
Q1 25
-2.3%
-91.6%
Q4 24
1.9%
-203.6%
Q3 24
23.7%
-41.2%
Q2 24
11.0%
4.7%
Q1 24
7.6%
-66.5%
Capex Intensity
CTKB
CTKB
NEWT
NEWT
Q4 25
1.6%
0.1%
Q3 25
1.3%
0.0%
Q2 25
3.5%
0.1%
Q1 25
2.0%
0.1%
Q4 24
1.6%
0.6%
Q3 24
2.0%
0.4%
Q2 24
2.3%
0.1%
Q1 24
1.3%
0.1%
Cash Conversion
CTKB
CTKB
NEWT
NEWT
Q4 25
-29.64×
Q3 25
-9.35×
Q2 25
-14.58×
Q1 25
-6.48×
Q4 24
0.21×
-8.35×
Q3 24
14.05×
-2.15×
Q2 24
0.27×
Q1 24
-4.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTKB
CTKB

Products$46.6M75%
Services$15.5M25%

NEWT
NEWT

Segment breakdown not available.

Related Comparisons